Figure 5
From: Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer
Riluzole inhibits migration of PMN into tumors in a 4T1 mouse model. 4T1 mouse TNBC cells were injected into the mammary fat pads of BALB/c mice and allowed to grow until tumors reached a mean size of 100 mm3 and then divided into groups of 6 and treated daily with either vehicle (DMSO), riluzole (18 mg/kg) or sunitinib (20 mg/kg) as a positive control, for 14 days. Tumors were measured and digested in collagenase/DNase and TANs detected by FACS analysis labeling with anti-Ly6G FITC-conjugated antibody. Both riluzole and sunitinib significantly increased tumor PMN presence (A) which coincided with tumor burden as previously published19. Results are the mean ± SEM where *is P < 0.05 compared to vehicle treated mice. (B) Representative scatter plot of treated cells staining positive for Ly6G+ (FITC+).
